Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society

Submitted by amarin on Mon, 08/23/2021 - 07:15
Home
News
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) …
VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced

Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology

Submitted by amarin on Mon, 08/16/2021 - 11:00
Home
News
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patie…
Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven Presentations DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of

Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update

Submitted by amarin on Thu, 08/05/2021 - 10:00
Home
News
Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides…
Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany Filed Several Market Access Dossiers in Europe with Proposed Pricing of approximately €200 per Month New CEO, Karim Mikhail, to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Aug.

Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021

Submitted by amarin on Thu, 07/15/2021 - 10:35
Home
News
Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host C…
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter and six month 2021 financial results and provide an

Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021

Submitted by amarin on Wed, 06/02/2021 - 20:31
Home
News
Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique For…
Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in Europe DUBLIN, Ireland and BRIDGEWATER, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc

Amarin to Present at Two Investor Conferences in June 2021

Submitted by amarin on Tue, 05/18/2021 - 10:06
Home
News
Amarin to Present at Two Investor Conferences in June 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim Mikhail, Amarin’s senior vice president and head of commercial for Europe and future president

Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session

Submitted by amarin on Mon, 05/17/2021 - 20:06
Home
News
Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) a…
REDUCE-IT ® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels Patients randomized to VASCEPA in EVAPORATE trial, in analyses of percent atheroma volume
Subscribe to